Jokath (Timolol, Travoprost)

Timolol blocks beta‑adrenergic receptors in the eye, reducing the production of aqueous humor. Travoprost activates prostaglandin F2α receptors, increasing uveoscleral outflow of fluid. Together, they provide a complementary mechanism that more effectively lowers intraocular pressure than either agent alone.

The dosing regimen for Jokath is determined by the prescribing ophthalmologist based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for Jokath in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Jokath, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Jokath combines a beta‑blocker (timolol) with a prostaglandin analog (travoprost), offering dual mechanisms of pressure reduction. Compared with single‑agent drops, this combination can achieve greater intraocular pressure lowering, potentially reducing the need for multiple separate medications and improving adherence.

Jokath should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product if the solution appears discolored or contains particles.

Jokath is applied as an eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid to create a small pocket, and instill one drop into the conjunctival sac of each prescribed eye. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe allergic reactions, worsening of glaucoma leading to vision loss, macular edema, systemic effects such as bradycardia, chest pain, or bronchospasm, especially in patients with underlying cardiac or respiratory disease. Any sudden visual changes or systemic symptoms should prompt immediate medical evaluation.

Jokath is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients in the formulation. It should also be avoided in individuals with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, second‑ or third‑degree heart block, or those taking systemic non‑selective beta‑blockers without medical supervision.